Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

New Drug Update for The Week Ending June 29

7/2/2019

 
Regulatory Update

In June 2019, the FDA rejected Acer Therapeutics’ celiprolol (Edsivo) for the treatment of Ehlers-Danlos syndrome and requested a new clinical trial be completed.

Nabriva announced the EMA accepted the MAA for lefamulin in June 2019 for treating community-acquired pneumonia.

Aimmune submitted an MAA for AR101 to the EMA in June 2019. AR101 is Aimmune’s Oral Immunotherapy used to desensitize the patient with peanut allergy.

Announced Research Updates


Conatus announced that in the 48-week, 217 patient, Phase IIb, ENCORE-LF trial, emricasan did not improve a composite endpoint of all-cause mortality, new decompensation events, or ≥4 points progression in the MELD score compared to placebo in NASH patients with compensated or early decompensated liver cirrhosis and severe portal hypertension. As in the original ENCORE-PF trial, there was no improvement in the hepatic venous pressure gradient after an additional 24 weeks of treatment with emricasan.

Proxel announced that in the 16-week, 215 patient, Phase III, TIMES 3 trial, imeglimin in combination with insulin decreased HbA1c 0.6% in Japanese patients with type 2 diabetes

Published Research Updates


In a 12-week, 616 patient Phase IIb, dose ranging trail trial, more patients treated with Alder Biopharmaceuticals’ eptinezumab 300 mg achieved a 75% or > decease in migraine days compared to placebo (33.1% vs 20.7%), but there was no difference with 100mg, 30mg and 10 mg in patients with chronic migraine. 

In the 255 patient, Phase III ADMYRE trial, PharmaMar’s plitidepsin plus dexamethasone did not improve progression free survival or overall survival compared to dexamethasone monotherapy in patients with multiple myeloma.

A lasmiditan safety analysis of 4,439 patients that participated in the Phase III SPARTAN and SAMURAI trials focused on dizziness and found that dizziness increased with dose was mostly mild or moderate in severity. Dizziness did not affect efficacy. The occurrence was 8.6% with 50 mg, 14.9% with 100 mg and 16.8% with 200 mg compared to 2.9% with placebo. The median time to onset was 30-40 minutes, with a median duration of 1.5-2 hours. Besides dose, risk factors for dizziness were non-Hispanic/Latino, mild or moderate severity of migraine attack, and lower body mass index.

In a 12-week, 365 patient, Phase II trial, treatment with Daiichi Sankyo/Exelixis’ esaxerenone 1.25 mg, 2.5 mg, and 5 mg reduced urinary albumin-to-creatinine ratio 38%, 50%, and 56% compared with 7% with placebo in Japanese patients with type 2 diabetes mellitus and microalbuminuria. 

In a 12-week, 363 patient, Phase IIb trial, 8.6% of patients treated with Cassiopea’s clascoterone, 1% and 8.3% of patients treated with clascoterone 0.1% had at least a two-grade improvement and achieved a clear or almost clear score with the Investigator’s Global Assessment in patients with facial acne.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.